Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
DNA diagnostics is being used in several applications due to its wide spectrum of applications such as in diagnosis of infectious diseases, oncologycancer, myogenic disorders, prenatal diagnostics, pre-implantation diagnostics, etc. The developed and developing economies are the most potential economies for the growth of DNA diagnostics. Growing awareness about healthcare and the need for cost-effective diagnostic solutions & accurate & faster test results in the fast growing economies have contributed to the growth of the market.
Additionally, rising incidences of chronic and infectious diseases, demand for automated instruments and growing governments? expenditures for providing healthcare facilities are also contributing to the growth of the DNA diagnostics market. Personalized medicine uses of the individual?s genetic profile and to prevent, treat and diagnose diseases. It is a medical mode which uses molecular analysis for medical decisions and practices.
Diagnosis of a disease is often based on symptoms which may not be specific and would be an indication of several diseases. The use of genetic information has played a pivotal role in the field of personalized medicine. The report highlights the adoption of DNA Diagnostics in Asia Pacific. Based on the Product Types, the Asia Pacific DNA Diagnostics Market is segmented into Instruments,
Reagents and Service & software segment. Based on the Application, the market is bifurcated into Oncology, Infectious disease testing, Myogenic disorder diagnosis, Clinical confirmation diagnostics, Prenatal diagnosis, Pre-implantation diagnostics and other segments. Based on the Technology, the market is bifurcated into PCR, Microarrays, In situ hybridization, Sequencing Technology, Mass Spectrometry and other segments.
Further, the market is segmented into POC (Point-of-Care), Central Laboratories and Self-Testing segments based on the End Users. The countries included in the report are China, Japan, India, South Korea, Singapore, Malaysia and Rest of Asia Pacific.
Key Players profiled in the report includes Sysmex Corporation, Bayer Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid Inc, Hologic Corporation, Illumina, Novartis International Ag, Thermo Fisher Scientific Inc. and Bio-Rad Laboratories.